DalsnaFinance

CCRM, OmniaBio and Avectas Partner to Improve Cell Therapy Manufacturing

Markets PR Newswire By PR Newswire 15 Jun 2026 12:00 1 min read
CCRM, OmniaBio and Avectas Partner to Improve Cell Therapy Manufacturing

DUBLIN and TORONTO, June 15, 2026 /PRNewswire/ - CCRM and its CDMO subsidiary OmniaBio Inc., today announced an agreement with Avectas Limited ("Avectas") to evaluate its automated, integrated and scalable cell therapy manufacturing platform. The evaluation will explore how Avectas'...

DUBLIN and TORONTO, June 15, 2026 /PRNewswire/ - CCRM and its CDMO subsidiary OmniaBio Inc., today announced an agreement with Avectas Limited ("Avectas") to evaluate its automated, integrated and scalable cell therapy manufacturing platform. The evaluation will explore how Avectas'...

Read the full story on PR Newswire → Opens the original article on www.prnewswire.com

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.